Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis

JAMA Dermatology

Volumn 151, Issue 7, 2015, Pages 753-760

  Moy, Andrea Primiani ^a   Murali, Mandakolathur ^a   Kroshinsky, Daniela ^a   Duncan, Lyn M ^a   Nazarian, Rosalynn M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASONUCLIN; BASONUCLIN 2; CD3 ANTIGEN; CD4 ANTIGEN; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; BNC2 PROTEIN, HUMAN; DNA BINDING PROTEIN; GATA3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CELLS BY BODY ANATOMY; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE EXACERBATION; ERYTHRODERMIC PSORIASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY; TH17 CELL; TH22 CELL; ADOLESCENT; ERYTHRODERMA; HELPER CELL; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PSORIASIS; TH1 CELL; TH2 CELL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD4; DERMATITIS, ATOPIC; DERMATITIS, EXFOLIATIVE; DNA-BINDING PROTEINS; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PHENOTYPE; PSORIASIS; RETROSPECTIVE STUDIES; STAT3 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH17 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 84937611431     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.2     Document Type: Article

References (38)

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1)(suppl 1):S86-S93.
2. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3)(suppl 2):S67-S80.
3. Ram-Wolff C, Martin-Garcia N, Bensussan A, Bagot M, Ortonne N. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol. 2010;32(8):755-763.
4. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211.
5. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
6. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189.
7. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-411.
8. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
9. Langley RG, Elewski BE, Lebwohl M, et al ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
10. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-2630.
11. Toda M, Leung DY, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol. 2003;111(4):875-881.
12. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857-863.
13. H17 T cells. J Allergy Clin Immunol. 2009;123(6):1244-1252.e2.
14. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092-1102.
15. Sigurdsson V, de Vries IJM, Toonstra J, et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol. 2000;27(9):436-440.
16. Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005;5:5.
17. Botella-Estrada R, Sanmartín O, Oliver V, Febrer I, Aliaga A. Erythroderma: a clinicopathological study of 56 cases. Arch Dermatol. 1994;130(12):1503-1507.
18. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008;181(10):7420-7427.
19. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111(4):645-649.
20. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319-324.
21. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373-1383.
22. Eyerich K, Pennino D, Scarponi C, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2009;123(1):59-66.e4. doi: 10.1016/j.jaci.2008.10.031.
23. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. NEngl J Med. 2002;347(15):1151-1160.
24. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol. 2005;125(6):1163-1173.
25. + T cells lacking IL-17 production. Proc Natl Acad Sci U S A. 2009;106(51):21795-21800.
26. H2 cells. Nat Immunol. 2009;10(8):864-871.
27. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not twins. Trends Immunol. 2010;31(9):354-361.
28. Sabat R, Sterry W, Philipp S, Wolk K. Three decades of psoriasis research: where has it led us? Clin Dermatol. 2007;25(6):504-509.
29. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. J Mol Med (Berl). 2009;87(5):523-536.
30. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg. 2010;29(1):3-9.
31. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis, part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420-1432.
32. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-150.
33. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255.
34. Lundin A, Fredens K, Michaëlsson G, Venge P. The eosinophil granulocyte in psoriasis. Br J Dermatol. 1990;122(2):181-193.
35. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573-3585.
36. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898.
37. Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13(11):777-789.
38. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974-982.